SR One
QuietFiled to raiseWayne, PABiotech & pharma, Medical devices, Digital healthLast fund filed 2025
2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Synapse InvestmentFiled to raise in 2025, with no closing reported yet. | 2025 | Indefinite | $0 | 0 |
| SR One Capital Fund III | October 2024 | $600M | $247M | 45 |
| SR One Capital Opportunities Fund IFiled to raise in 2023, with no closing reported yet. | 2023 | Indefinite | $0 | 0 |
| AMZLFiled to raise in 2023, with no closing reported yet. | 2023 | Indefinite | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
3 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Matthew FoyNot on the current fund | Quiet | Biotech & pharma | 2 |
Categories of SR One’s own portfolio companies, based on 20 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of SR One’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Vivo Capital | 2 | ADARx Pharmaceuticals, TP Therapeutics |
| Abingworth Bioventures | 1 | EFFECTOR THERAPEUTICS |
| Aisling Capital | 1 | Dren Bio |
| Atlas Venture | 1 |
| SR One Capital Fund II-A | November 2021 | Indefinite | $83M | 25 |
| SR One Capital Fund II-B | September 2021 | Indefinite | $399M | 35 |
| SR One Capital Fund I-BFiled to raise in 2020, with no closing reported yet. | 2020 | $400M | $0 | 0 |
| SR One Capital Fund I-AFiled to raise in 2020, with no closing reported yet. | 2020 | $400M | $0 | 0 |
| 0 |
| Rajeev Dadoo | Quiet | Biotech & pharma, Digital health, Medical devices | 8 | 0 |
| Simeon George | Quiet | Biotech & pharma, Medical devices | 11 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| Navitor Pharmaceuticals |
| Bain Capital Life Sciences | 1 | ADARx Pharmaceuticals |
| Kleiner Perkins | 1 | Auxogyn |
| Monograph Capital Partners | 1 | Auxogyn |
| Samsara Biocapital | 1 | Principia Biopharma |
| Sofinnova Venture Partners | 1 | EFFECTOR THERAPEUTICS |
| TCG Crossover | 1 | ADARx Pharmaceuticals |
| The Column Group | 1 | EFFECTOR THERAPEUTICS |
| U.S Venture Partners | 1 | EFFECTOR THERAPEUTICS |
| Venbio Global Strategic | 1 | TP Therapeutics |
| Versant Venture Capital | 1 | CRISPR Therapeutics AG |
| Vida Ventures | 1 | Auxogyn |
A shared board seat: a company where filings name a SR One partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.